17,261 trials
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Carcinoma · Stage IV Renal Cell Cancer
Primary: Progression-free Survival at 24 Weeks — 52; 27 percentage of participants
HIV Infection · Bone Loss · Osteopenia
Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml
Non-Small Cell Lung Cancer Stage IV
Primary: Progression Free Survival (PFS) — 2.53; 4.21 months — p=0.0068
Nausea · Vomiting · Glioma
Primary: Proportion of Patients Achieving Complete Control (CC) — 0.59; 0.55 proportion of patients
Multiple Myeloma
Primary: The Clinical Benefit Response (CBR) — 1; 1; 0; 12 Participants
Meningococcal Disease
Primary: Percentage of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US Neisseria Meningitidis (N. Meningitidis) Serogroup B Strain at One Month After the…
End Stage Renal Disease · Kidney Failure · Delayed Graft Function
Primary: Number of Patients Enrolled With Serum Creatinine >3mg/dL on Postoperative Day 5. — 29; 32 Participants
Chronic Sinusitis
Primary: Number of Sinuses With Successful Implant Delivery — 10 Sinuses
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Complete Response Rate of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) and Pralatrexate (P) Treatment — 52 percentage of participants analyzed
Sarcoma
Primary: Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria. — 12.4 Weeks
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) — 3.0; 4.3; 3.8; 4.8 percentage of participants
Treatment for Prevention of Chronic Migraine
Primary: Change From Baseline in Monthly Migraine Days — -4.18; -6.64; -6.63 migraine days / month — p=<0.001
Vulvovaginal Candidiasis
Primary: Summary of Injection Site Reactions for the Safety Population Over the 12-months Post Vaccination Period — 72; 79; 10; 25 AEs
Non Small Cell Lung Cancer
Primary: Overall Survival — 29; 27; 13; 13 Participants — p=0.2069
Pancreatic Cancer
Primary: Overall Survival (OS) — 8.02; 9.82; 10.45 months